Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LPO | P22079 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19622429 | 0.81 | KMT2A (0.35) | ALDH1A1KMT2APOLBCYP3A4CYP2E1 | |
| SCHEMBL28036586 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KMT2APOLBCYP3A4CYP2E1 | |
| SCHEMBL14459642 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KMT2APOLBCYP3A4CYP2E1 | |
| SCHEMBL17616423 | 0.78 | ALDH1A1 (0.33) | ALDH1A1KMT2APOLBCYP3A4CYP2E1 | |
| Ammonia Solution, Strong SCHEMBL29243780 | 0.76 | ALDH1A1 (0.35) | ALDH1A1KMT2APOLBCYP3A4CYP2E1 | |
| SCHEMBL23867480 | 0.76 | FDPS (0.38) | ALDH1A1KMT2APOLBFDPSLMNA | |
| SCHEMBL27393599 | 0.76 | FDPS (0.38) | ALDH1A1KMT2APOLBCYP3A4CYP2E1 | |
| SCHEMBL17544451 | 0.76 | ALDH1A1 (0.32) | ALDH1A1KMT2APOLBCYP3A4CYP2E1 | |
| SCHEMBL20254223 | 0.76 | ALDH1A1 (0.36) | ALDH1A1KMT2APOLBCYP3A4CYP2E1 | |
| SCHEMBL17621579 | 0.74 | ALDH1A1 (0.32) | ALDH1A1KMT2APOLBCYP3A4CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742168-B2 | Process for the production of acetic acid | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2014-06-03 | — | — | US | claimed |
| US-8637699-B2 | Process for the manufacture of acetic acid | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2014-01-28 | — | — | US | claimed |
| US-20120310009-A1 | Process for the Production of Acetic Acid | LYONDELL CHEMICAL COMPANY (US) | 2012-12-06 | — | — | US | claimed |
| US-20120264971-A1 | PROCESS FOR THE MANUFACTURE OF ACETIC ACID | LYONDELLBASELL ACETYLS, LLC | 2012-10-18 | — | — | US | claimed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024050433-A1 | ALLOSTERIC MODULATORS OF ANDROGEN RECEPTOR COACTIVATOR RECRUITMENT FOR CRPC THERAPY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-03-07 | — | — | WO | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| EP-0006463-B1 | PROCESS FOR THE PRODUCTION OF 2-SUBSTITUTED 1-ALKYL-NITROIMIDAZOLES | BASF Aktiengesellschaft (DE) | 1981-11-25 | — | — | EP | disclosed |
| US-4267349-A | Process for the preparation of 2-substituted-alkyl-1-alkyl-nitroimidazoles | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-12 | — | — | US | disclosed |
| US-4232165-A | 2-Substituted-1-alkyl-nitroimidazoles | BASF AKTIENGESELLSCHAFT (DE) | 1980-11-04 | — | — | US | disclosed |
| EP-0006463-A1 | Process for the production of 2-substituted 1-alkyl-nitroimidazoles | BASF Aktiengesellschaft (DE) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | ALDH1A1 1656/4885KMT2A 2996/4885POLB 4702/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | ALDH1A1 3804/4885KMT2A 1250/4885POLB 2944/4885 |
| US-20120264971-A1 | PROCESS FOR THE MANUFACTURE OF ACETIC ACID | DBI, IDH1, ACAD9 | ALDH1A1 69/4885KMT2A 1300/4885POLB 117/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ALDH1A1 2211/4885KMT2A 2172/4885POLB 4196/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | ALDH1A1 3235/4885KMT2A 1296/4885POLB 1540/4885 |
| US-20120310009-A1 | Process for the Production of Acetic Acid | DBI, FLI1, ACADM | ALDH1A1 52/4885KMT2A 1534/4885POLB 465/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | ALDH1A1 1936/4885KMT2A 2759/4885POLB 2560/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | ALDH1A1 3688/4885KMT2A 754/4885POLB 3131/4885 |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GRIN1, GRM2, GRM1 | ALDH1A1 1395/4885KMT2A 2334/4885POLB 3092/4885 |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRDT, RBX1 | ALDH1A1 4038/4885KMT2A 1311/4885POLB 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.